Pharmacogenomics

CPIC Guideline CPIC

TRCPIC Kılavuzu
Also known as:Clinical Pharmacogenetics Implementation Consortium Guideline

A peer-reviewed, evidence-based prescribing recommendation issued by the Clinical Pharmacogenetics Implementation Consortium for a specific gene–drug pair.

In depth

CPIC guidelines assume that a genotype result is already available and focus on the practical question of what to prescribe: whether to use a standard dose, adjust the dose, choose an alternative drug, or intensify monitoring for each metabolizer or risk phenotype. Recommendations are graded by strength of evidence and are periodically revised as new pharmacogenomic and clinical outcome data emerge.

CPIC guidelines cover well-established pairs such as CYP2D6–codeine, CYP2C19–clopidogrel, HLA-B*57:01–abacavir, HLA-B*15:02–carbamazepine, TPMT/NUDT15–thiopurines, DPYD–fluoropyrimidines, and VKORC1/CYP2C9–warfarin, and are widely used alongside similar guidance from other consortia, such as the Dutch Pharmacogenetics Working Group.

Clinical pearl

CPIC deliberately does not recommend for or against ordering a test; it only tells the prescriber what to do once a genotype result is already in hand.

Example drugs

Clopidogrel Codeine Abacavir Carbamazepine Warfarin
TRIn Turkish

CPIC Kılavuzu

Klinik Farmakogenetik Uygulama Konsorsiyumu (CPIC) tarafından belirli bir gen–ilaç çifti için yayımlanan, kanıta dayalı ve hakemli bir reçeteleme önerisidir.

CPIC kılavuzları bir genotip sonucunun zaten elde edilmiş olduğunu varsayar ve her metabolizör veya risk fenotipi için ne reçete edileceği pratik sorusuna odaklanır: standart doz mu kullanılacak, doz mu ayarlanacak, alternatif bir ilaç mı seçilecek, yoksa izlem mi yoğunlaştırılacak. Öneriler kanıt gücüne göre derecelendirilir ve yeni farmakogenomik ve klinik sonuç verileri ortaya çıktıkça periyodik olarak güncellenir.

CPIC kılavuzları; CYP2D6–kodein, CYP2C19–klopidogrel, HLA-B*57:01–abakavir, HLA-B*15:02–karbamazepin, TPMT/NUDT15–tiyopürinler, DPYD–floropirimidinler ve VKORC1/CYP2C9–varfarin gibi köklü gen–ilaç çiftlerini kapsar ve Hollanda Farmakogenetik Çalışma Grubu gibi diğer konsorsiyumların benzer kılavuzlarıyla birlikte yaygın olarak kullanılır.

CPIC kasıtlı olarak bir testin istenip istenmemesi konusunda öneride bulunmaz; yalnızca genotip sonucu elde edildikten sonra reçete yazan kişiye ne yapması gerektiğini bildirir.

Updated 24.09.2026 0 views Educational reference — verify against current sources before clinical use.

Read next

PharmacogenomicsFarmakogenomik

The study of how inherited genetic variation affects an individual's response to drugs, used clinically to guide drug and dose selection.

 Activity ScoreAktivite Skoru

A numeric value, assigned to each allele and summed across a diplotype, used mainly for CYP2D6 to translate genotype into a predicted metabolizer phenotype.

 CYP2D6CYP2D6

A highly polymorphic cytochrome P450 enzyme that metabolises a large number of drugs, including several opioids and antidepressants, and activates key prodrugs.

 CYP2C19CYP2C19

A cytochrome P450 enzyme that activates the prodrug clopidogrel to its antiplatelet metabolite and also metabolises proton pump inhibitors and several other drugs.

 HLA-B*57:01HLA-B*57:01

A human leukocyte antigen allele strongly associated with a severe, immune-mediated hypersensitivity reaction to the antiretroviral drug abacavir.

 DPYDDPYD

The gene encoding dihydropyrimidine dehydrogenase, the rate-limiting enzyme for inactivating fluoropyrimidine chemotherapy drugs, whose deficiency risks severe toxicity.